{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:35:09Z","timestamp":1789929309834,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.lungcan.2017.09.014","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T06:02:08Z","timestamp":1506578528000},"page":"115-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study"],"prefix":"10.1016","volume":"113","author":[{"given":"Toby","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dangoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason F.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cipelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Summerhayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Newsom-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2017.09.014_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.13-S1-28","article-title":"Considerations for second-line therapy of non-small cell lung cancer","volume":"13","author":"Stinchcombe","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11864-016-0437-x","article-title":"From 2000 to 2016: which second-line treatment in advanced non-small cell lung cancer?","volume":"17","author":"D\u2019Argento","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0015","article-title":"Second-line chemotherapy for non-small cell lung cancer","author":"Bonfill","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-016-0365-z","article-title":"Emerging therapeutic agents for lung cancer","volume":"9","author":"Dholaria","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0025","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","article-title":"Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer: a systematic review and meta-analysis","volume":"34","author":"Dammeijer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0030","series-title":"Neutropenic Sepsis: Prevention and Management in People with Cancer (CG151)","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0035","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.09.014_bib0040","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"ESMO guidelines working group, management of febrile neutropenia: ESMO clinical practice guidelines","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/sj.bjc.6604863","article-title":"The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis","volume":"100","author":"Wailoo","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000327711","article-title":"Management of febrile neutropenia-a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer","volume":"34","author":"Ihbe-Heffinger","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0060","series-title":"Governance Arrangements for Research Ethics Committees: A Harmonised Edition","author":"Department of Health","year":"2012"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2141.2011.08693.x","article-title":"Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit","volume":"153","author":"Clarke","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0070","series-title":"Common Terminology Criteria for Adverse Events (v4.03)","author":"National Institutes of Health","year":"2010"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0075","series-title":"British National Formulary 71 (March 2016\u2013September 2016)","author":"Joint Formulary Committee","year":"2016"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0080","series-title":"NHS National Tariff Payment System 2016\/17","author":"NHS England","year":"2016"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0085","series-title":"NHS Reference Costs 2014\u20132015","author":"Department of Health","year":"2015"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0090","series-title":"Evidence for Policy and Practice Information and Co-ordination (EPPI) Centre Cost Converter v.1.4","author":"Campbell and Cochrane Economics Methods Group (CCEMG)","year":"2016"},{"key":"10.1016\/j.lungcan.2017.09.014_bib0095","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","article-title":"Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre","volume":"23","author":"Schelenz","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.09.014_bib0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/2040620715613715","article-title":"The evolving role of biosimilars in haematology-oncology: a practical perspective","volume":"6","author":"Gascon","year":"2015","journal-title":"Ther. Adv Hematol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2017.09.014_bib0105","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T21:24:02Z","timestamp":1668633842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217305251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"alternative-id":["S0169500217305251"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.09.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}